<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id><journal-title-group><journal-title>BMC Neurology</journal-title></journal-title-group><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6190553</article-id><article-id pub-id-type="publisher-id">1149</article-id><article-id pub-id-type="doi">10.1186/s12883-018-1149-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Comorbidity of migraine with ADHD in adults</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Hansen</surname><given-names>Thomas Folkmann</given-names></name><address><phone>+45 22825659</phone><email>Thomas.hansen@regionh.dk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Hoeffding</surname><given-names>Louise K.</given-names></name><address><email>Louise.K.Enggaard.Hoeffding@regionh.dk</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kogelman</surname><given-names>Lisette</given-names></name><address><email>Lisette.kogelman@regionh.dk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Haspang</surname><given-names>Thilde Marie</given-names></name><address><email>thilde.marie.haspang@regionh.dk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ullum</surname><given-names>Henrik</given-names></name><address><email>Henrik.Ullum@regionh.dk</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>S&#x000f8;rensen</surname><given-names>Erik</given-names></name><address><email>Erik.Soerensen@regionh.dk</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Erikstrup</surname><given-names>Christian</given-names></name><address><email>christian.erikstrup@skejby.rm.dk</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Pedersen</surname><given-names>Ole Birger</given-names></name><address><email>olbp@regionsjaelland.dk</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nielsen</surname><given-names>Kaspar Ren&#x000e9;</given-names></name><address><email>k.nielsen@rn.dk</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Hjalgrim</surname><given-names>Henrik</given-names></name><address><email>HHJ@ssi.dk</email></address><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Paarup</surname><given-names>Helene M.</given-names></name><address><email>helene.paarup@rsyd.dk</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6703-7762</contrib-id><name><surname>Werge</surname><given-names>Thomas</given-names></name><address><email>thomas.werge@regionh.dk</email></address><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Burgdorf</surname><given-names>Kristoffer</given-names></name><address><email>kristoffer.soelvsten.burgdorf@regionh.dk</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0646 7373</institution-id><institution-id institution-id-type="GRID">grid.4973.9</institution-id><institution>Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, </institution><institution>University Hospital of Copenhagen, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0674 042X</institution-id><institution-id institution-id-type="GRID">grid.5254.6</institution-id><institution>Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, </institution><institution>University of Copenhagen, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0646 7373</institution-id><institution-id institution-id-type="GRID">grid.4973.9</institution-id><institution>Department of Clinical Immunology, the Blood Bank, Rigshospitalet, </institution><institution>University Hospital of Copenhagen, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0512 597X</institution-id><institution-id institution-id-type="GRID">grid.154185.c</institution-id><institution>Department of Clinical Immunology, </institution><institution>Aarhus University Hospital, </institution></institution-wrap>Aarhus, Denmark </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0631 4668</institution-id><institution-id institution-id-type="GRID">grid.416369.f</institution-id><institution>Department of Clinical Immunology, </institution><institution>Naestved Hospital, </institution></institution-wrap>Naestved, Denmark </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0646 7349</institution-id><institution-id institution-id-type="GRID">grid.27530.33</institution-id><institution>Department of Clinical Immunology, </institution><institution>Aalborg University Hospital, </institution></institution-wrap>Aalborg, Denmark </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0417 4147</institution-id><institution-id institution-id-type="GRID">grid.6203.7</institution-id><institution>Department of Epidemiology Research, </institution><institution>Statens Serum Institut, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0646 7373</institution-id><institution-id institution-id-type="GRID">grid.4973.9</institution-id><institution>Department of Hematology, </institution><institution>Copenhagen University Hospital, </institution></institution-wrap>Rigshospitalet, Copenhagen, Denmark </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0512 5013</institution-id><institution-id institution-id-type="GRID">grid.7143.1</institution-id><institution>Department of Clinical Immunology, </institution><institution>Odense University Hospital, </institution></institution-wrap>Odense, Denmark </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0646 7373</institution-id><institution-id institution-id-type="GRID">grid.4973.9</institution-id><institution>Institute of Biological Psychiatry, Mental Health Centre Sct. Hans, </institution><institution>Copenhagen University Hospital, </institution></institution-wrap>Roskilde, Denmark </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0674 042X</institution-id><institution-id institution-id-type="GRID">grid.5254.6</institution-id><institution>Department of Clinical Medicine, </institution><institution>University of Copenhagen, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff12"><label>12</label>The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Copenhagen, Denmark </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0646 7373</institution-id><institution-id institution-id-type="GRID">grid.4973.9</institution-id><institution>Danish Headache Center, Neurological department, </institution><institution>Copenhagen University Hospital, </institution></institution-wrap>Nordre Ringevej 69, DK-2600 Glostrup, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>18</volume><elocation-id>147</elocation-id><history><date date-type="received"><day>20</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Migraine and Attention Deficit and Hyperactivity Disorder (ADHD) have been found to be associated in child and adolescent cohorts; however, the association has not been assessed in adults or otherwise healthy population. Assessing the comorbidity between ADHD and migraine may clarify the etiopathology of both diseases. Thus, the objective is to assess whether migraine (with and without visual disturbances) and ADHD are comorbid disorders.</p></sec><sec><title>Methods</title><p id="Par2">Participants from the Danish Blood Donor Study (<italic>N</italic>&#x02009;=&#x02009;26,456, age 18&#x02013;65, 46% female) were assessed for migraine and ADHD using the ASRS ver 1.1 clinically validated questionnaire and self-reported migraine in a cross-sectional study. Logistic regression was used to examine the comorbidity between migraine and ADHD, and their associated endophenotypes.</p></sec><sec><title>Results</title><p id="Par3">Migraine was strongly associated with ADHD (OR&#x02009;=&#x02009;1.8, 95% CI&#x02009;=&#x02009;1.5&#x02013;2.1), (238/6152 vs 690/19,376). There was a significant interaction between age and gender, with comorbidity increasing with age and female sex. Post-hoc analysis showed that migraine with visual disturbance was generally associated with a marginally higher risk of ADHD and this was independent of ADHD endophenotypes.</p></sec><sec><title>Conclusion</title><p id="Par4">Migraine and ADHD were demonstrated to be comorbid disorders; the association with ADHD was most prominent for participants with migraine with visual disturbances. Future studies will elucidate which genetic and environmental factors contribute to migraine-ADHD comorbidity.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Migraine</kwd><kwd>Attention deficiency and hyperactivity disorder</kwd><kwd>Comorbidity</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005275</institution-id><institution>Region Hovedstaden</institution></institution-wrap></funding-source><award-id>R129-A3973</award-id><principal-award-recipient><name><surname>Hansen</surname><given-names>Thomas Folkmann</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Candy foundation </institution></funding-source><award-id>CHEAD</award-id><principal-award-recipient><name><surname>Hansen</surname><given-names>Thomas Folkmann</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003554</institution-id><institution>Lundbeckfonden</institution></institution-wrap></funding-source><award-id>R219-2016-1030</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008392</institution-id><institution>Sundhed og Sygdom, Det Frie Forskningsr&#x000e5;d</institution></institution-wrap></funding-source><award-id>1333-00275A</award-id><award-id>09-069412</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par12">Migraine is a complex and multifactorial headache disorder with a lifetime prevalence of 16&#x02013;18% [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Migraine is twice as prevalent in females, and onset is typically between adolescence and the late 50s [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. According to the World Health Organization (WHO), migraine is the sixth most disabling disease in the world with high financial costs to society [<xref ref-type="bibr" rid="CR4">4</xref>]. Response to acute treatment varies considerably and approximately 20% of the pharmacologically treated patients experience no symptom relief after medication [<xref ref-type="bibr" rid="CR5">5</xref>]. There are two major endophenotypes in migraine: migraine with or without aura. Aura is a sensory disturbance, which is predominantly seen as visual disturbances (99%) with a subsequent headache or migraine [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par13">Attention deficit and hyperactivity disorder (ADHD) is characterized by inappropriate levels of inattention, e.g., difficulty keeping attention, keeping track of details, and difficulty structuring trivial duties or following instructions, hyperactivity, e.g., speaks a lot, difficulty relaxing or sitting still, and impulsivity, e.g., often interrupts other people during conversations or answers a question before the question is finished [<xref ref-type="bibr" rid="CR8">8</xref>]. In contrast to migraine, ADHD has an early onset and a pooled worldwide prevalence of 5.3% in child and adolescent populations [<xref ref-type="bibr" rid="CR9">9</xref>]. The current treatment strategies do not completely remove the symptoms in both children and adults and approximately 30% of all patients do not respond to medical treatment or develop serious adverse reactions [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par14">It is well established that migraine is comorbid with psychiatric traits, in particular depressive and bipolar disorder [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], and that the comorbidity is partly explained by shared genetics [<xref ref-type="bibr" rid="CR14">14</xref>]. More recently, the comorbidity between migraine and ADHD has also been assessed [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. In adults, a clinical case-control study of ADHD (<italic>n</italic>&#x02009;=&#x02009;572/675) found an increased prevalence of migraine when compared to community controls [<xref ref-type="bibr" rid="CR16">16</xref>], and subsequently the same investigators showed a positive association between prescription of anti-migraine and anti-ADHD drugs to adults in the total Norwegian population(<italic>n</italic>&#x02009;&#x0003e;&#x02009;4mill) [<xref ref-type="bibr" rid="CR17">17</xref>]. In line with this, Arruda et al. reported a higher prevalence of ADHD among children with migraine (5&#x02013;12&#x000a0;years) than for non-headache individuals in a pediatric population cohort (<italic>n</italic>&#x02009;=&#x02009;5671) [<xref ref-type="bibr" rid="CR19">19</xref>]. According to the recently published meta-analysis including child and adolescence studies and the Fasmer et al. adult study, there is a positive association between migraine and ADHD with odds-ratio of 1.3 [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par15">Using a cross-sectional study of adults (age 18&#x02013;65&#x000a0;years), we test the hypothesis that migraine is comorbid with ADHD in 26,456 participants using clinically validated questionnaires.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Participants</title><p id="Par16">From November 2015 to September 2017 voluntary blood donors were recruited as part of the Danish Blood Donor Study (DBDS) (<ext-link ext-link-type="uri" xlink:href="http://www.dbds.dk">www.DBDS.dk</ext-link>). In brief, the DBDS was initiated in 2010 and is an ongoing prospective research cohort and biobank that recruits participants between 17 and 67&#x000a0;years of age from blood banks across Denmark [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Individuals in chronic medical treatment or frequent travelers to countries considered resulting in high-risk of blood disease are not allowed to participate. Approximately 95% of all invited individuals are consented to participate in DBDS [<xref ref-type="bibr" rid="CR22">22</xref>]. At enrolment, each individual gives oral and written informed consent to participate in DBDS and subsequently answers a digital tablet-based questionnaire including a migraine (two questions) and an ADHD (18 questions) module. In total, 29,489 participants were recruited to the study. The study is approved by the Danish Data Protection Agency (2007&#x02013;58-0015) and the Ethical Committee of Central Denmark (M-20090237). For further details about the DBDS platform and questionnaire, see Pedersen et al. [<xref ref-type="bibr" rid="CR22">22</xref>] or Burgdorf et al. [<xref ref-type="bibr" rid="CR21">21</xref>]</p><p id="Par17">In total, 29,489 participants were given a questionnaire. We excluded 3033 individuals due to missing answers on either the SQM (<italic>n</italic>&#x02009;=&#x02009;2057) or the ASRS items (<italic>n</italic>&#x02009;=&#x02009;1108) of which <italic>n</italic>&#x02009;=&#x02009;132 were missing both. The excluded individuals did not differ significantly with respect to age (chi-square test, <italic>P</italic>-value&#x02009;=&#x02009;0.24) compared to the study population. The excluded individuals were slightly older (median age: 44&#x000a0;years, IQR&#x02009;=&#x02009;31&#x02013;54&#x000a0;years) when compared to the study population (median age: 42&#x000a0;years, IQR&#x02009;=&#x02009;30&#x02013;52&#x000a0;years) (Wilcoxon test, <italic>P</italic>-value&#x02009;=&#x02009;3.7e-8). Importantly, the frequency of migraine in individuals excluded because of missing information in the ASRS questionnaire was similar to that of the study population (24.1%). Further, the frequency of ADHD in individuals excluded because of missing items in the SQM questionnaire was similar to that of the study population 4.2%.</p></sec><sec id="Sec4"><title>The migraine module</title><p id="Par18">The presence of migraine was evaluated by two questions from the population screening questionnaire for migraine (SQM). The participants were asked two questions (&#x0201c;Have you ever had migraine?&#x0201d; and &#x0201c;Have you ever had visual disturbances lasting 5-60 min followed by headache?&#x0201d;) of the original SQM. Participants who had a positive response to either of the two questions were considered to have migraine and are referred as migraine cases in this study. Individuals with missing information or who answered &#x0201c;I don&#x02019;t know&#x0201d; were excluded. A detailed description of the SQM questionnaire can be found elsewhere [<xref ref-type="bibr" rid="CR23">23</xref>]. In short, the SQM has previously been shown to identify 93% of those with migraine with aura and 75% of those with migraine without aura in a Danish setting [<xref ref-type="bibr" rid="CR23">23</xref>]. Using the national prescription register, we found that 89.5% of those prescribed migraine-specific treatment, i.e. triptans ATC-codes N02CC01&#x02013;7, are captured using these two questions.</p></sec><sec id="Sec5"><title>The ADHD module</title><p id="Par19">Current self-reported ADHD symptoms were assessed using the current national recommendation for clinical assessment of adults by using the ADHD Self-Report Scale v1.1 (ASRS) [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] translated to Danish Dalsgaard et al. [<xref ref-type="bibr" rid="CR26">26</xref>]. The ASRS consists of 18 items based on the <italic>Diagnostic and Statistical Manual of Mental Disorders fourth edition</italic> (DSM-IV) diagnostic criteria for ADHD and is the recommended version for clinical use in Denmark. Each of the 18 questions was scored on a five-point Likert scale ranging from never&#x02009;=&#x02009;0 to very often&#x02009;=&#x02009;4. In this study we use the optimal Kessler et al. 18-item ASRS scale score obtained by summarizing all items (total range of 0&#x02013;72) as the primary outcome. The ASRS has been validated in multiple countries using different populations [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. The scale dichotomizes ADHD based upon all items for ADHD (having a score&#x02009;&#x0003e;&#x02009;36), inattentive subtype (items 1&#x02013;4&#x02009;+&#x02009;7&#x02013;11, having a score&#x02009;&#x0003e;&#x02009;23), the hyperactivity-impulsivity subtype (items 5&#x02013;6&#x02009;+&#x02009;12&#x02013;18, having a score&#x02009;&#x0003e;&#x02009;23), and the 6-item screening score (having a score&#x02009;&#x0003e;&#x02009;13) [<xref ref-type="bibr" rid="CR28">28</xref>]. A more detailed description of the ASRS questionnaire can be found elsewhere [<xref ref-type="bibr" rid="CR24">24</xref>].</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par20">The study population was described by numbers and percentages for categorical variables and as median and interquartile range (IQR) for continuous variables. Differences in distributions between participants with and without migraine and ADHD symptoms were analyzed using Fisher&#x02019;s exact test or Mann-Whitney/Wilcoxon test (age does not follow a normal distribution, thus non-parametric analysis is used).</p><p id="Par21">Logistic regression was used to analyze the association between migraine and ADHD (dichotomous variables) in the study population, adjusting for age, sex, and the interaction between sex and age, with migraine as the dependent variable. We used a logistic regression model with a binary outcome of either migraine, migraine with visual disturbance, or migraine without visual disturbances. We did not include sampling weights, as these are not available for DBDS. We calculatedthe regression in two ways including age as a quantitative trait or as a categorical trait (10&#x000a0;year interval). We report the derived odds ratios (OR) and 95% confidence intervals (CIs). A <italic>P</italic>-value&#x0003c;&#x02009;0.05 was considered statistically significant. Post-hoc analyses were performed using different thresholds of the ASRS score (from 0 and 52), and single ASRS items (data not shown). To check if the specified model is appropriate for the data, the predicted and observed residuals were inspected for each analysis and no issues were observed.</p><p id="Par22">All statistical analyses were performed using the statistical package for R version 3.3.3: stat, basic, ggplot2, eeptools, cowplot, and GirdExtra.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Study population</title><p id="Par23">The population consisted of 26,456 participants (median age: 42&#x000a0;years, IQR&#x02009;=&#x02009;30&#x02013;52&#x000a0;years) from the DBDS, of whom 24.2% screened positive for migraine (median age: 42&#x000a0;years, IQR&#x02009;=&#x02009;31&#x02013;51&#x000a0;years, female-to-male ratio: 1:0.6), 2.61% screened positive for ADHD (median age: 29&#x000a0;years, IQR&#x02009;=&#x02009;25&#x02013;40&#x000a0;years, female-to-male ratio: 1:1.4), and 0.90% reported having both migraine and ADHD (median age: 31&#x000a0;years, IQR&#x02009;=&#x02009;24&#x02013;41&#x000a0;years, male-to-female ratio: 1:0.74), see Table <xref rid="Tab1" ref-type="table">1</xref> for the prevalence. There was a significant difference in the age and sex distributions for participants with either migraine or ADHD (Wilcoxon test and chi-square exact, <italic>P</italic>&#x02009;&#x0003c;&#x02009;1e-15 and <italic>P</italic>&#x02009;&#x0003c;&#x02009;1e-15, respectively) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>), thus we included a correction for age, sex and interaction of age and sex in the model.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of the study population (<italic>N</italic>&#x02009;=&#x02009;26,456) with respect to migraine and ADHD symptoms</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="5">N</th><th/></tr><tr><th>Description</th><th colspan="2">Female (%<sup>e</sup>)</th><th>Male</th><th>Total</th><th>(%<sup>f</sup>)</th><th><italic>P</italic>-value<sup>d</sup></th></tr></thead><tbody><tr><td>The total study population</td><td>12,247</td><td>(46.3)</td><td>14,209</td><td>26,456</td><td>(100)</td><td/></tr><tr><td>Migraine<sup>a</sup></td><td>4024</td><td>(63.0)</td><td>2366</td><td>6390</td><td>(24.2)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>- <italic>Without visual disturbances</italic></td><td>2187</td><td>(62.0)</td><td>1343</td><td>3530</td><td>(13.3)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>- <italic>With visual disturbances</italic></td><td>1832</td><td>(64.2)</td><td>1019</td><td>2851</td><td>(10.8)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>ADHD<sup>b</sup></td><td>285</td><td>(41.3)</td><td>405</td><td>690</td><td>(2.6)</td><td>0.0085</td></tr><tr><td>- <italic>Inattention</italic></td><td>83</td><td>(39.7)</td><td>126</td><td>209</td><td>(0.79)</td><td>0.06</td></tr><tr><td>- <italic>Hyperactivity-impulsivity</italic></td><td>67</td><td>(43.0)</td><td>89</td><td>156</td><td>(0.59)</td><td>0.42</td></tr><tr><td>- <italic>Screening items</italic><sup><italic>c</italic></sup></td><td>182</td><td>(26.7)</td><td>400</td><td>682</td><td>(2.58)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Migraine and ADHD</td><td>137</td><td>(57.6)</td><td>101</td><td>238</td><td>(0.90)</td><td>&#x0003c;&#x02009;0.001</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Symptoms of migraine was assessed by the SQM [<xref ref-type="bibr" rid="CR19">19</xref>],<sup>b</sup> ADHD symptoms were assessed by the ASRS [<xref ref-type="bibr" rid="CR20">20</xref>], <sup>c</sup> Screening as described by Kessing et al. [<xref ref-type="bibr" rid="CR23">23</xref>], <sup>d</sup> Test of gender differences of total population and subgroup by chi-square test, <sup>e</sup> percentage females of the subgrup, <sup>f</sup> percentage of the total sample</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Age distribution. The X-axis shows age from 17 to 66&#x000a0;years, the Y-axis shows the proportional distribution by age of the study population, colored according to phenotype status on the right</p></caption><graphic xlink:href="12883_2018_1149_Fig1_HTML" id="MO1"/></fig></p><p id="Par24">There was an association between migraine and ADHD symptoms with OR&#x02009;=&#x02009;1.81 (95CI%: 1.53&#x02013;2.12, <italic>P</italic>&#x02009;=&#x02009;1.4e-14) including corrections for age, sex and the interaction of age and sex as covariates (Table <xref rid="Tab2" ref-type="table">2</xref>a). As expected, male sex is protective (OR&#x02009;=&#x02009;0.57), and increased age further increased protection with OR&#x02009;=&#x02009;9.99 per year (Table <xref rid="Tab2" ref-type="table">2</xref>a). To ease literature comparison, we present the sex-stratified results (Table <xref rid="Tab2" ref-type="table">2</xref>b + c) and repeated the regression analysis using age bins (10&#x000a0;years), see Table <xref rid="Tab3" ref-type="table">3</xref>. The association was not explained by one specific item in the ASRS questionnaire (data not shown). The highest risk was found for migraine with visual disturbances and ADHD symptoms (OR&#x02009;=&#x02009;2.05, 95CI%: 1.55&#x02013;2.68, <italic>P</italic>&#x02009;=&#x02009;3.3e-11). Using the national prescription register we did not find any difference in frequency of triptan purchases with and without ADHD symptoms (at least one purchase: 22.1% vs 23.2%, <italic>p</italic>&#x02009;=&#x02009;0.80, at least 2 purchases: 13.7% vs 14.4%, and at least 10 purchases: 3.2% vs 4.9%, <italic>p</italic>&#x02009;=&#x02009;0.39).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Multivariable Logistic regression analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th>
<italic>Model</italic>
</th><th/><th colspan="3">
<italic>a) All genders</italic>
</th><th colspan="3">
<italic>b) Females only</italic>
</th><th colspan="3">
<italic>c) Males only</italic>
</th></tr><tr><th>Outcome</th><th>
<italic>Variable</italic>
</th><th>
<italic>OR</italic>
</th><th>
<italic>CI 95%</italic>
</th><th>
<italic>P-value</italic>
</th><th>
<italic>OR</italic>
</th><th>
<italic>CI 95%</italic>
</th><th>
<italic>P-value</italic>
</th><th>
<italic>OR</italic>
</th><th>
<italic>CI 95%</italic>
</th><th>
<italic>P-value</italic>
</th></tr></thead><tbody><tr><td rowspan="4">Migraine</td><td>ADHD</td><td>1.81</td><td>1.53&#x02013;2.12</td><td>&#x0003c;&#x02009;0.001</td><td>2.01</td><td>1.58&#x02013;2.54</td><td>&#x0003c;&#x02009;0.001</td><td>1.64</td><td>1.30&#x02013;2.06</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Age</td><td>1.00</td><td>1.00&#x02013;1.01</td><td>0.001</td><td>1.01</td><td>1.00&#x02013;1.01</td><td>&#x0003c;&#x02009;0.001</td><td>1.00</td><td>0.99&#x02013;1.00</td><td>0.051</td></tr><tr><td>Gender (Male)</td><td>0.57</td><td>0.47&#x02013;0.69</td><td>&#x0003c;&#x02009;0.001</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Age:Gender (Male)</td><td>0.99</td><td>0.99&#x02013;0.99</td><td>&#x0003c;&#x02009;0.001</td><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="4">With Visual Disturbances</td><td>ADHD</td><td>1.98</td><td>1.61&#x02013;2.41</td><td>&#x0003c;&#x02009;0.001</td><td>2.05</td><td>1.55&#x02013;2.68</td><td>&#x0003c;&#x02009;0.001</td><td>1.89</td><td>1.38&#x02013;2.53</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Age</td><td>1.00</td><td>1.00&#x02013;1.00</td><td>0.84</td><td>1.00</td><td>1.00&#x02013;1.00</td><td>0.11</td><td>1.00</td><td>0.99&#x02013;1.00</td><td>0.11</td></tr><tr><td>Gender (Male)</td><td>0.53</td><td>0.40&#x02013;0.69</td><td>&#x0003c;&#x02009;0.001</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Age:Gender (Male)</td><td>1.00</td><td>0.99&#x02013;1.00</td><td>0.16</td><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="4">Without Visual Disturbances</td><td>ADHD</td><td>1.52</td><td>1.22&#x02013;1.88</td><td>&#x0003c;&#x02009;0.001</td><td>1.69</td><td>1.24&#x02013;2.27</td><td>&#x0003c;&#x02009;0.001</td><td>1.37</td><td>0.99&#x02013;1.86</td><td>0.047</td></tr><tr><td>Age</td><td>1.01</td><td>1.00&#x02013;1.01</td><td>&#x0003c;&#x02009;0.001</td><td>1.01</td><td>1.00&#x02013;1.01</td><td>&#x0003c;&#x02009;0.001</td><td>1.00</td><td>0.99&#x02013;1.00</td><td>0.23</td></tr><tr><td>Gender (Male)</td><td>0.63</td><td>0.49&#x02013;0.82</td><td>&#x0003c;&#x02009;0.001</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Age:Gender (Male)</td><td>0.99</td><td>0.98&#x02013;1.00</td><td>&#x0003c;&#x02009;0.001</td><td/><td/><td/><td/><td/><td/></tr></tbody></table><table-wrap-foot><p>Multivariable Logistic regression analysis of migraine and migraine with and without visual disturbances, subsequent stratified on gender.</p><p>Reference of the regression model is given in ()</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Multivariable logistic regression analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th>
<italic>Outcome</italic>
</th><th>
<italic>Variable</italic>
</th><th>
<italic>OR</italic>
</th><th>
<italic>CI 95%</italic>
</th><th>
<italic>P-value</italic>
</th></tr></thead><tbody><tr><td rowspan="11">Migraine</td><td>ADHD</td><td>1,86</td><td>1,58-2,19</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Age 3X<sup>a</sup></td><td>1,34</td><td>1,20-1,51</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Age 4X<sup>a</sup></td><td>1,59</td><td>1,43-1,76</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Age 5X<sup>a</sup></td><td>1,27</td><td>1,14-1,42</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Age 60&#x02009;+&#x02009;<sup>a</sup></td><td>0,98</td><td>0,84-1,15</td><td>0.80</td></tr><tr><td>Gender (Male)</td><td>0,49</td><td>0,44-0,56</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td colspan="3">Gender (Male) interaction with:</td><td/></tr><tr><td>Age 3X<sup>a</sup></td><td>0,78</td><td>0,66-0,93</td><td>0.007</td></tr><tr><td>Age 4X<sup>a</sup></td><td>0,75</td><td>0,63-0,88</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Age 5X<sup>a</sup></td><td>0,75</td><td>0,63-0,89</td><td>0.0013</td></tr><tr><td>Age 60&#x02009;+&#x02009;<sup>a</sup></td><td>0,84</td><td>0,66-1,07</td><td>0.16</td></tr><tr><td>With Visual Disturbances</td><td>ADHD</td><td>2,01</td><td>1,63-2,45</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td/><td>Age 3X<sup>a</sup></td><td>1,13</td><td>0,97-1,31</td><td>0.110</td></tr><tr><td rowspan="9"/><td>Age 4X<sup>a</sup></td><td>1,20</td><td>1,05-1,38</td><td>0.0095</td></tr><tr><td>Age 5X<sup>a</sup></td><td>1,13</td><td>0,98-1,31</td><td>0.090</td></tr><tr><td>Age 60&#x02009;+&#x02009;<sup>a</sup></td><td>0,78</td><td>0,63-0,97</td><td>0.028</td></tr><tr><td>Gender (Male)</td><td>0,49</td><td>0,41-0,57</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td colspan="4">Gender (Male) interaction with:</td></tr><tr><td>Age 3X<sup>a</sup></td><td>0,90</td><td>0,71-1,15</td><td>0.41</td></tr><tr><td>Age 4X<sup>a</sup></td><td>0,83</td><td>0,66-1,05</td><td>0.13</td></tr><tr><td>Age 5X<sup>a</sup></td><td>0,79</td><td>0,62-1,01</td><td>0.06</td></tr><tr><td>Age 60&#x02009;+&#x02009;<sup>a</sup></td><td>1,12</td><td>0,80-1,57</td><td>0.5</td></tr><tr><td>Without Visual Disturbances</td><td>ADHD</td><td>1,59</td><td>1,28-1,97</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td/><td>Age 3X<sup>a</sup></td><td>1,47</td><td>1,27-1,70</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td rowspan="9"/><td>Age 4X<sup>a</sup></td><td>1,81</td><td>1,59-2,07</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Age 5X<sup>a</sup></td><td>1,34</td><td>1,16-1,54</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Age 60&#x02009;+&#x02009;<sup>a</sup></td><td>1,15</td><td>0,94-1,39</td><td>0.16</td></tr><tr><td>Gender (Male)</td><td>0,53</td><td>0,46-0,63</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td colspan="4">Gender (Male) interaction with:</td></tr><tr><td>Age 3X<sup>a</sup></td><td>0,73</td><td>0,58-0,92</td><td>0.0069</td></tr><tr><td>Age 4X<sup>a</sup></td><td>0,72</td><td>0,59-0,89</td><td>0.0026</td></tr><tr><td>Age 5X<sup>a</sup></td><td>0,75</td><td>0,60-0,93</td><td>0.011</td></tr><tr><td>Age 60&#x02009;+&#x02009;<sup>a</sup></td><td>0,69</td><td>0,50-0,94</td><td>0.021</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Reference is age&#x02009;&#x0003c;&#x02009;30</p></table-wrap-foot></table-wrap></p><p id="Par25">The association between migraine and ADHD symptoms was statistically significant irrespective of the employed ASRS score threshold (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>), with a tendency to increase with the ASRS score. The same results were observed for ADHD symptoms and migraine with visual disturbances (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>), however; no association was detected for migraine without visual disturbances with ASRS scores below 10 and above 51 (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>The odds ratio of the multivariable regression analysis at each ASRS score. X-axis presents the ASRS score. The vertical red dotted line marks the threshold for ADHD for the optimal 18-item score. Left Y-axis is the Odds Ratio indicated as the black line and the 95% confidence interval by the grey area. All analysis is done with multivariable logistic regression adjusting for age, sex and the interaction of age and sex</p></caption><graphic xlink:href="12883_2018_1149_Fig2_HTML" id="MO2"/></fig></p><p id="Par26">Migraine was associated with both ADHD endophenotypes (inattention and hyperactivity-impulsivity), with migraine with visual disturbances showing a marginally larger effect than migraine without visual disturbances, notably with overlapping confidence intervals (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Analysis of ADHD and Migraine endophenotypes. X-axes are odds ratio (black dot) and 95% confidence intervals (black lines) with a grey vertical line indicating an odds ratio of 1. The three graphs display migraine, and migraine with and without visual disturbances. The Y-axis displays the ADHD and two ADHD endophenotypes</p></caption><graphic xlink:href="12883_2018_1149_Fig3_HTML" id="MO3"/></fig></p></sec></sec><sec id="Sec9"><title>Discussion</title><p id="Par27">We address the comorbidity of migraine and ADHD symptoms in a healthy population of 29,489 adults using two clinically validated questionnaires (SQM and ASRS). Our results show a strong and statistically significant comorbidity between the two disorders which was irrespective of the threshold (i.e., not restricted to the commonly used ASRS score threshold of 37 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). The regression model clearly shows that being male protects against migraine and increased age is further protective as seen in the interaction between age and sex (Table <xref rid="Tab2" ref-type="table">2</xref>). Stratified analyses suggested that the observed comorbidity was more pronounced in migraineurs experiencing visual disturbances; however, no differences in association with migraine were seen for the two ADHD endophenotypes (inattention and hyperactivity-impulsivity).</p><p id="Par28">The current study significantly supplements the sparse literature regarding the comorbidity between migraine and ADHD in adults by using a large, healthy study population of individuals who have not been exposed to chronic treatment for migraine or for ADHD. It supports the meta-analysis by Salem et al., showing OR of 1.3, consisting primarily of child and adolescence studies. This meta-analysis cohort consisted of a clinical case-control cohort, (<italic>n</italic>&#x02009;=&#x02009;572) with ADHD [<xref ref-type="bibr" rid="CR16">16</xref>], and a cross-sectional study using prescription data on anti-migraine and anti-ADHD drugs from the entire Norwegian population [<xref ref-type="bibr" rid="CR17">17</xref>]. Thus, the comorbidity between migraine and ADHD seems present both in and out of a clinical setting. The origin of the comorbidity is not obvious and typical prognostic features such as the age of onset, and the female-to-male ratio of the two diseases are somewhat contradicting. It has previously been suggested that the co-occurrence of migraine and ADHD originates from common pathophysiological mechanisms potentially related to dysfunctions in the dopaminergic system [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. This arises because many of the migraine symptoms, including prodromal symptoms, can be provoked with dopamine receptor stimulation, and some can even be quantified in rat models with dopaminergic activiation [<xref ref-type="bibr" rid="CR31">31</xref>]. Dopamine has long been thought to be involved in ADHD pathology, and the effective ADHD drug, methylphenidate, acts by inhibiting dopamine reuptake. However, the comorbidity could also be more complex because of common co-morbidities of other psychiatric disorders such as anxiety and mood disorders [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. Their etiological comorbidity may arise because of pleiotropic factors. This has recently been supported by Antilla et al., showing a significant genetic correlation between migraine and ADHD [<xref ref-type="bibr" rid="CR37">37</xref>]. Interestingly, major depressive disorder was also found to significantly correlate with both migraine and ADHD suggesting that common pleiotropic factors exist.</p><p id="Par29">The observed prevalence of migraine and ADHD (34.7%) was higher than reported by Fasmer et al. (28.3%) in a sample of ADHD patients with similar age and sex distribution [<xref ref-type="bibr" rid="CR16">16</xref>]. However, there is an anecdote among headache individuals with headache that donating blood gives symptom relief, which could explain the frequency of migraine, i.e. bloodletting by phlebotomy. Furthermore, we used self-reported ADHD rather than formal clinical diagnoses in our analysis, which may influence the results with false positive and negative cases. Despite these methodological differences, we found the prevalence of self-reported migraine and ADHD symptoms in males (24% vs. 23%) to be like that reported by Fasmer et al. [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par30">We found that the comorbidity between migraine and ADHD was most prevalent among participants peaking at 52 to 53&#x000a0;years of age, and in the 40 decade compared to the 17&#x02013;29 age group, which is somewhat inversely correlated with the age distribution of ADHD symptoms in the study population (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). This could imply that the manifestations of comorbid migraine and ADHD occur rather late in life when compared to ADHD in general, or that ADHD symptoms mask the presence of migraine in the younger participants. Similar results have been reported by Fasmer et al. [<xref ref-type="bibr" rid="CR17">17</xref>] using simultaneous prescriptions of anti-migraine and anti-ADHD medication as a proxy for comorbidity. However, this was not true for the 10&#x02013;19&#x000a0;years age group, suggesting that ADHD among adolescents may have no comorbidity with migraine and thus having a distinct etiopathology or, as previously mentioned, there is a masking of migraine symptoms in young individuals with ADHD. The notion of a different etiopathology among ADHD patients is suggested by Johansson et al. (Johansson et al. 2008), showing that susceptibility genes differ between persistent and juvenile ADHD [<xref ref-type="bibr" rid="CR38">38</xref>]. Furthermore, the transition of ADHD symptoms from childhood to adulthood is well recognized where the hyperactivity-impulsivity often becomes less prominent.</p><p id="Par31">We did not detect a specific association between any ADHD endophenotypes and migraine which is congruent with previous reports for children, e.g., Pakainis et al. and Arruda et al [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] It is noteworthy that we do not see a large difference between ADHD inattention and hyperactive endophenotype. Although speculative, the smaller difference between hyperactive and inattention endophenotype in the study cohort could reflect that the inattention is more often referred to treatment and thus are not permitted to donate blood [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par32">Participants reporting migraine preceded by visual disturbances (migraine with visual aura symptoms) were more often affected by co-occurring ADHD symptoms when compared to participants reporting no visual disturbances and combined (Table <xref rid="Tab2" ref-type="table">2</xref>, Fig. <xref rid="Fig2" ref-type="fig">2</xref>). No obvious shared mechanism between visual disturbances and ADHD symptoms is known. The neurovascular phenomenon cortical depression spreading is suggested as the pathophysiology of aura symptoms in migraine patients [<xref ref-type="bibr" rid="CR41">41</xref>], however, there are no published studies on ADHD patients. Ophthalmologic disturbances appear to be more frequent in patients diagnosed with ADHD [<xref ref-type="bibr" rid="CR42">42</xref>], however, it is very speculative whether this could explain the observed comorbidity and further studies are needed.</p><p id="Par33">The strength of the study is the large sample size and that chronic treatment of migraine and ADHD do not influence the results, e.g., treatment-induced migraine attacks. Furthermore, we used validated questionnaires to assess migraine and ADHD symptoms. In accordance with Danish clinical guides we use the recommended version of ASRS to assess ADHD. While a new version based on DSM V exists, a recent study found almost identical specificity and sensitivity of the two versions [<xref ref-type="bibr" rid="CR43">43</xref>]. Furthermore, we show that 89% of individuals using triptans are captured, and the prevalence of triptan users in migraineurs with and without ADHD symptoms is the same. When interpreting the results, it is important to take into consideration that the study population is a healthy donor population, presumably producing a conservative estimate of the association as individuals exposed to chronic medication or chronic illness are excluded as donors. Further, we suggest carrying out longitudinal cohort and twin studies to assess causality.</p></sec><sec id="Sec10"><title>Conclusion</title><p id="Par34">We demonstrate a significant corbobidity between migraine and ADHD in adults, and this is most prominent for participants with migraine with visual disturbances. These results contribute to the understanding of genetic correlation seen between ADHD and migraine and seeds future studies that will elucidate which genetic and environmental factors contribute to migraine-ADHD comorbidity.</p></sec><sec id="Sec11"><title>Article highlights</title><p id="Par35">
<list list-type="bullet"><list-item><p id="Par36">This study examined the association between migraine and ADHD in a large adult population</p></list-item><list-item><p id="Par37">There is a strong association between migraine and ADHD (odds ratio&#x02009;=&#x02009;1.8, 95% CI&#x02009;=&#x02009;1.5&#x02013;2.1)</p></list-item><list-item><p id="Par38">The association between migraine and ADHD seems strongest for individuals with visual disturbances</p></list-item></list>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>95%CI95</term><def><p id="Par5">Confidence interval</p></def></def-item><def-item><term>ADHD </term><def><p id="Par6">Attention Deficit and Hyperactivity Disorder</p></def></def-item><def-item><term>ASRS</term><def><p id="Par7">ADHD Self-Report Scale</p></def></def-item><def-item><term>IQR</term><def><p id="Par8">Interquartile range</p></def></def-item><def-item><term>OR</term><def><p id="Par9">Odss Ratio</p></def></def-item><def-item><term>SQM</term><def><p id="Par10">Screening questionnaire for migraine</p></def></def-item><def-item><term>WHO</term><def><p id="Par11">World Health Organization</p></def></def-item></def-list></glossary><ack><p>We acknowledge the Danish blood donors and the staff at the Danish blood banks involved in the present study. We thank Shantel Weinsheimer for reviewing the final manuscript.</p><sec id="FPar1"><title>Funding</title><p id="Par39">This work was supported by RegionH research foundation (R129-A3973 to Dr. Hansen); Candy foundation CEHEAD (Prof Jes Olesen, Co-PI Dr. Hansen); the Lundbeck Foundation, Denmark under Grant (R219&#x02013;2016&#x02013;1030 to Dr. Hoeffding); The Danish Council for Independent Research - Medical Sciences under Grant (1333-00275A to Dr. Burgdorf and 09&#x02013;069412); The Danish Administrative Regions; The Danish Administrative Regions&#x02019; Bio- and Genome Bank; and The Danish Blood Donor Research Foundation (Bloddonorernes Forskningsfond). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par40">The data that support the findings of this study are available from DBDS but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of DBDS steering committee and the Ethical Committee of Central Denmark.</p></sec></ack><notes notes-type="author-contribution"><title>Authors contributions</title><p>TFH, LKH, study design and analysis. LK and TMH statistical design and analysis. HU, ES, CE, OBP, KRN, HH, HMP, TW, and KB study design. All authors contributed to creating this manuscript and approved the final version.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p>The study is approved by the Danish Data Protection Agency (2007&#x02013;58-0015) and the Ethical Committee of Central Denmark (M-20090237). All participants gave informed oral and written consent to participate.</p></sec><sec id="FPar4"><title>Consent for publication</title><p>NA</p></sec><sec id="FPar5"><title>Competing interests</title><p>TW: has served as a lecturer for and consultant to H. Lundbeck A/S.</p><p>TFH, LKH,KB,LK,TMH,HH,HMP,KRN,OBP,CE,ES,HU and TW reports no competing interest.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlof</surname><given-names>C</given-names></name><name><surname>Linde</surname><given-names>M</given-names></name></person-group><article-title>One-year prevalence of migraine in Sweden: a population-based study in adults</article-title><source>Cephalalgia</source><year>2001</year><volume>21</volume><fpage>664</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2001.00218.x</pub-id><pub-id pub-id-type="pmid">11531898</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagen</surname><given-names>K</given-names></name><name><surname>Zwart</surname><given-names>JA</given-names></name><name><surname>Vatten</surname><given-names>L</given-names></name><name><surname>Stovner</surname><given-names>LJ</given-names></name><name><surname>Bovim</surname><given-names>G</given-names></name></person-group><article-title>Prevalence of migraine and non-migrainous headache--head-HUNT, a large population-based study</article-title><source>Cephalalgia</source><year>2000</year><volume>20</volume><fpage>900</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2000.00145.x</pub-id><pub-id pub-id-type="pmid">11304025</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>MB</given-names></name><name><surname>Rasmussen</surname><given-names>BK</given-names></name><name><surname>Thorvaldsen</surname><given-names>P</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group><article-title>Prevalence and sex-ratio of the subtypes of migraine</article-title><source>Int J Epidemiol</source><year>1995</year><volume>24</volume><fpage>612</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1093/ije/24.3.612</pub-id><pub-id pub-id-type="pmid">7672904</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustavsson</surname><given-names>A</given-names></name><name><surname>Svensson</surname><given-names>M</given-names></name><name><surname>Jacobi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Cost of disorders of the brain in Europe 2010</article-title><source>Eur Neuropsychopharmacol</source><year>2011</year><volume>21</volume><fpage>718</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2011.08.008</pub-id><pub-id pub-id-type="pmid">21924589</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldman</surname><given-names>AD</given-names></name><name><surname>Smith</surname><given-names>LA</given-names></name><name><surname>McQuay</surname><given-names>HJ</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name></person-group><article-title>Pharmacological treatments for acute migraine: quantitative systematic review</article-title><source>Pain</source><year>2002</year><volume>97</volume><fpage>247</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(02)00024-6</pub-id><pub-id pub-id-type="pmid">12044621</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1&#x02013;211.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>MB</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group><article-title>A nosographic analysis of the migraine aura in a general population</article-title><source>Brain</source><year>1996</year><volume>119</volume><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1093/brain/119.2.355</pub-id><pub-id pub-id-type="pmid">8800932</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Organization WH. International Statistical Classification of Diseases and Related Health Problems: tenth revision-Version for 2007. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/classifications/icd/en/">http://www.who.int/classifications/icd/en/</ext-link>. Accessed 1 Dec 2017.</mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polanczyk</surname><given-names>G</given-names></name><name><surname>de Lima</surname><given-names>MS</given-names></name><name><surname>Horta</surname><given-names>BL</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Rohde</surname><given-names>LA</given-names></name></person-group><article-title>The worldwide prevalence of ADHD: a systematic review and metaregression analysis</article-title><source>Am J Psychiatry</source><year>2007</year><volume>164</volume><fpage>942</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1176/ajp.2007.164.6.942</pub-id><pub-id pub-id-type="pmid">17541055</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maia</surname><given-names>CR</given-names></name><name><surname>Cortese</surname><given-names>S</given-names></name><name><surname>Caye</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long-term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD</article-title><source>J Atten Disord</source><year>2017</year><volume>21</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1177/1087054714559643</pub-id><pub-id pub-id-type="pmid">25501355</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>T</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Wilens</surname><given-names>T</given-names></name><etal/></person-group><article-title>A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder</article-title><source>Biol Psychiatry</source><year>2005</year><volume>57</volume><fpage>456</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2004.11.043</pub-id><pub-id pub-id-type="pmid">15737659</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonaci</surname><given-names>F</given-names></name><name><surname>Nappi</surname><given-names>G</given-names></name><name><surname>Galli</surname><given-names>F</given-names></name><name><surname>Manzoni</surname><given-names>GC</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name><name><surname>Costa</surname><given-names>A</given-names></name></person-group><article-title>Migraine and psychiatric comorbidity: a review of clinical findings</article-title><source>J Headache Pain</source><year>2011</year><volume>12</volume><fpage>115</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1007/s10194-010-0282-4</pub-id><?supplied-pmid 3072482?><pub-id pub-id-type="pmid">21210177</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jette</surname><given-names>N</given-names></name><name><surname>Patten</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Becker</surname><given-names>W</given-names></name><name><surname>Wiebe</surname><given-names>S</given-names></name></person-group><article-title>Comorbidity of migraine and psychiatric disorders--a national population-based study</article-title><source>Headache</source><year>2008</year><volume>48</volume><fpage>501</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2007.00993.x</pub-id><pub-id pub-id-type="pmid">18070059</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Heath</surname><given-names>AC</given-names></name><name><surname>Madden</surname><given-names>PA</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name><name><surname>Nyholt</surname><given-names>DR</given-names></name></person-group><article-title>Shared genetic factors underlie migraine and depression</article-title><source>Twin Res Hum Genet</source><year>2016</year><volume>19</volume><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1017/thg.2016.46</pub-id><?supplied-pmid 5436908?><pub-id pub-id-type="pmid">27302564</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arruda</surname><given-names>MA</given-names></name><name><surname>Guidetti</surname><given-names>V</given-names></name><name><surname>Galli</surname><given-names>F</given-names></name><name><surname>Albuquerque</surname><given-names>RC</given-names></name><name><surname>Bigal</surname><given-names>ME</given-names></name></person-group><article-title>Migraine, tension-type headache, and attention-deficit/hyperactivity disorder in childhood: a population-based study</article-title><source>Postgrad Med</source><year>2010</year><volume>122</volume><fpage>18</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.3810/pgm.2010.09.2197</pub-id><pub-id pub-id-type="pmid">20861584</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasmer</surname><given-names>OB</given-names></name><name><surname>Halmoy</surname><given-names>A</given-names></name><name><surname>Oedegaard</surname><given-names>KJ</given-names></name><name><surname>Haavik</surname><given-names>J</given-names></name></person-group><article-title>Adult attention deficit hyperactivity disorder is associated with migraine headaches</article-title><source>Eur Arch Psychiatry Clin Neurosci</source><year>2011</year><volume>261</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1007/s00406-011-0203-9</pub-id><?supplied-pmid 3225610?><pub-id pub-id-type="pmid">21394551</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasmer</surname><given-names>OB</given-names></name><name><surname>Riise</surname><given-names>T</given-names></name><name><surname>Lund</surname><given-names>A</given-names></name><name><surname>Dilsaver</surname><given-names>SC</given-names></name><name><surname>Hundal</surname><given-names>O</given-names></name><name><surname>Oedegaard</surname><given-names>KJ</given-names></name></person-group><article-title>Comorbidity of migraine with ADHD</article-title><source>J Atten Disord</source><year>2012</year><volume>16</volume><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1177/1087054710385784</pub-id><pub-id pub-id-type="pmid">21173430</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Instanes JT, Klungsoyr K, Halmoy A, Fasmer OB, Haavik J. Adult ADHD and comorbid somatic disease: a systematic literature review. J Atten Disord. 2016.</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Arruda MA, Arruda R, Guidetti V, Bigal ME. ADHD is comorbid to migraine in childhood: a population-based study. J Atten Disord. 2017:1087054717710767. <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/28587507">https://www.ncbi.nlm.nih.gov/pubmed/28587507</ext-link>.</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salem</surname><given-names>Haitham</given-names></name><name><surname>Vivas</surname><given-names>David</given-names></name><name><surname>Cao</surname><given-names>Fei</given-names></name><name><surname>Kazimi</surname><given-names>Iram F.</given-names></name><name><surname>Teixeira</surname><given-names>Antonio L.</given-names></name><name><surname>Zeni</surname><given-names>Cristian P.</given-names></name></person-group><article-title>ADHD is associated with migraine: a systematic review and meta-analysis</article-title><source>European Child &#x00026; Adolescent Psychiatry</source><year>2017</year><volume>27</volume><issue>3</issue><fpage>267</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1007/s00787-017-1045-4</pub-id><pub-id pub-id-type="pmid">28905127</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgdorf</surname><given-names>KS</given-names></name><name><surname>Felsted</surname><given-names>N</given-names></name><name><surname>Mikkelsen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Digital questionnaire platform in the Danish blood donor study</article-title><source>Comput Methods Prog Biomed</source><year>2016</year><volume>135</volume><fpage>101</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.cmpb.2016.07.023</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>OB</given-names></name><name><surname>Erikstrup</surname><given-names>C</given-names></name><name><surname>Kotze</surname><given-names>SR</given-names></name><etal/></person-group><article-title>The Danish blood donor study: a large, prospective cohort and biobank for medical research</article-title><source>Vox Sang</source><year>2012</year><volume>102</volume><fpage>271</fpage><pub-id pub-id-type="doi">10.1111/j.1423-0410.2011.01553.x</pub-id><pub-id pub-id-type="pmid">21967299</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gervil</surname><given-names>M</given-names></name><name><surname>Ulrich</surname><given-names>V</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Russell</surname><given-names>MB</given-names></name></person-group><article-title>Screening for migraine in the general population: validation of a simple questionnaire</article-title><source>Cephalalgia</source><year>1998</year><volume>18</volume><fpage>342</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1998.1806342.x</pub-id><pub-id pub-id-type="pmid">9731939</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>RC</given-names></name><name><surname>Adler</surname><given-names>L</given-names></name><name><surname>Ames</surname><given-names>M</given-names></name><etal/></person-group><article-title>The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population</article-title><source>Psychol Med</source><year>2005</year><volume>35</volume><fpage>245</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1017/S0033291704002892</pub-id><pub-id pub-id-type="pmid">15841682</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">NKR: Udredning og behandling af ADHD hos voksne. at <ext-link ext-link-type="uri" xlink:href="https://www.sst.dk/da/udgivelser/2015/nkr-adhd-hos-voksne">https://www.sst.dk/da/udgivelser/2015/nkr-adhd-hos-voksne</ext-link>. Accessed 1 Dec 2017.</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>L</given-names></name><name><surname>Jorgensen</surname><given-names>SL</given-names></name><name><surname>Dalsgaard</surname><given-names>S</given-names></name><name><surname>Bilenberg</surname><given-names>N</given-names></name></person-group><article-title>Danish standardization of the attention deficit hyperactivity disorder rating scale</article-title><source>Ugeskr Laeger</source><year>2009</year><volume>171</volume><fpage>1500</fpage><lpage>1504</lpage><pub-id pub-id-type="pmid">19419629</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>LA</given-names></name><name><surname>Spencer</surname><given-names>T</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name><etal/></person-group><article-title>Validity of pilot adult ADHD self- report scale (ASRS) to rate adult ADHD symptoms</article-title><source>Ann Clin Psychiatry</source><year>2006</year><volume>18</volume><fpage>145</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1080/10401230600801077</pub-id><pub-id pub-id-type="pmid">16923651</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>RC</given-names></name><name><surname>Adler</surname><given-names>LA</given-names></name><name><surname>Gruber</surname><given-names>MJ</given-names></name><name><surname>Sarawate</surname><given-names>CA</given-names></name><name><surname>Spencer</surname><given-names>T</given-names></name><name><surname>Van Brunt</surname><given-names>DL</given-names></name></person-group><article-title>Validity of the World Health Organization adult ADHD self-report scale (ASRS) screener in a representative sample of health plan members</article-title><source>Int J Methods Psychiatr Res</source><year>2007</year><volume>16</volume><fpage>52</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1002/mpr.208</pub-id><?supplied-pmid 2044504?><pub-id pub-id-type="pmid">17623385</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>EH</given-names></name><name><surname>Joung</surname><given-names>YS</given-names></name></person-group><article-title>The WHO adult ADHD self-report scale: reliability and validity of the Korean version</article-title><source>Psychiatry Investig</source><year>2013</year><volume>10</volume><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.4306/pi.2013.10.1.41</pub-id><?supplied-pmid 3590429?><pub-id pub-id-type="pmid">3590429</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonnby</surname><given-names>K</given-names></name><name><surname>Skordas</surname><given-names>K</given-names></name><name><surname>Olofsdotter</surname><given-names>S</given-names></name><name><surname>Vadlin</surname><given-names>S</given-names></name><name><surname>Nilsson</surname><given-names>KW</given-names></name><name><surname>Ramklint</surname><given-names>M</given-names></name></person-group><article-title>Validation of the World Health Organization adult ADHD self-report scale for adolescents</article-title><source>Nord J Psychiatry</source><year>2015</year><volume>69</volume><fpage>216</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.3109/08039488.2014.968203</pub-id><pub-id pub-id-type="pmid">25348323</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emilien</surname><given-names>G</given-names></name><name><surname>Maloteaux</surname><given-names>JM</given-names></name><name><surname>Geurts</surname><given-names>M</given-names></name><name><surname>Hoogenberg</surname><given-names>K</given-names></name><name><surname>Cragg</surname><given-names>S</given-names></name></person-group><article-title>Dopamine receptors--physiological understanding to therapeutic intervention potential</article-title><source>Pharmacol Ther</source><year>1999</year><volume>84</volume><fpage>133</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/S0163-7258(99)00029-7</pub-id><pub-id pub-id-type="pmid">10596903</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasmer</surname><given-names>OB</given-names></name></person-group><article-title>The prevalence of migraine in patients with bipolar and unipolar affective disorders</article-title><source>Cephalalgia</source><year>2001</year><volume>21</volume><fpage>894</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2001.00279.x</pub-id><pub-id pub-id-type="pmid">11903283</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasmer</surname><given-names>OB</given-names></name><name><surname>Oedegaard</surname><given-names>KJ</given-names></name></person-group><article-title>Clinical characteristics of patients with major affective disorders and comorbid migraine</article-title><source>World J Biol Psychiatry</source><year>2001</year><volume>2</volume><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.3109/15622970109026801</pub-id><pub-id pub-id-type="pmid">12587198</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>NC</given-names></name><name><surname>Du Fort</surname><given-names>GG</given-names></name><name><surname>Cervantes</surname><given-names>P</given-names></name></person-group><article-title>Prevalence, clinical correlates, and treatment of migraine in bipolar disorder</article-title><source>Headache</source><year>2003</year><volume>43</volume><fpage>940</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2003.03184.x</pub-id><pub-id pub-id-type="pmid">14511270</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breslau</surname><given-names>N</given-names></name><name><surname>Merikangas</surname><given-names>K</given-names></name><name><surname>Bowden</surname><given-names>CL</given-names></name></person-group><article-title>Comorbidity of migraine and major affective disorders</article-title><source>Neurology</source><year>1994</year><volume>44</volume><fpage>S17</fpage><lpage>S22</lpage></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>d'Onofrio</surname><given-names>F</given-names></name><name><surname>Barbanti</surname><given-names>P</given-names></name><name><surname>Petretta</surname><given-names>V</given-names></name><etal/></person-group><article-title>Migraine and movement disorders</article-title><source>Neurol Sci</source><year>2012</year><volume>33</volume><issue>Suppl 1</issue><fpage>S55</fpage><lpage>S59</lpage><pub-id pub-id-type="doi">10.1007/s10072-012-1042-9</pub-id><pub-id pub-id-type="pmid">22644172</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Brainstorm C, Anttila V, Bulik-Sullivan B, et al. Analysis of shared heritability in common disorders of the brain. Science. 2018:360.</mixed-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>S</given-names></name><name><surname>Halleland</surname><given-names>H</given-names></name><name><surname>Halmoy</surname><given-names>A</given-names></name><etal/></person-group><article-title>Genetic analyses of dopamine related genes in adult ADHD patients suggest an association with the DRD5-microsatellite repeat, but not with DRD4 or SLC6A3 VNTRs</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2008</year><volume>147B</volume><fpage>1470</fpage><lpage>1475</lpage><pub-id pub-id-type="doi">10.1002/ajmg.b.30662</pub-id><pub-id pub-id-type="pmid">18081165</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pakalnis</surname><given-names>A</given-names></name><name><surname>Gibson</surname><given-names>J</given-names></name><name><surname>Colvin</surname><given-names>A</given-names></name></person-group><article-title>Comorbidity of psychiatric and behavioral disorders in pediatric migraine</article-title><source>Headache</source><year>2005</year><volume>45</volume><fpage>590</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2005.05113.x</pub-id><?supplied-pmid 15953278?><pub-id pub-id-type="pmid">15953278</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millstein</surname><given-names>RB</given-names></name><name><surname>Wilens</surname><given-names>TE</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Spencer</surname><given-names>TJ</given-names></name></person-group><article-title>Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD</article-title><source>J Atten Disord</source><year>1997</year><volume>2</volume><fpage>159</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1177/108705479700200302</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauritzen</surname><given-names>M</given-names></name></person-group><article-title>Pathophysiology of the migraine aura. The spreading depression theory</article-title><source>Brain</source><year>1994</year><volume>117</volume><issue>Pt 1</issue><fpage>199</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1093/brain/117.1.199</pub-id><pub-id pub-id-type="pmid">7908596</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gronlund</surname><given-names>MA</given-names></name><name><surname>Aring</surname><given-names>E</given-names></name><name><surname>Landgren</surname><given-names>M</given-names></name><name><surname>Hellstrom</surname><given-names>A</given-names></name></person-group><article-title>Visual function and ocular features in children and adolescents with attention deficit hyperactivity disorder, with and without treatment with stimulants</article-title><source>Eye (Lond)</source><year>2007</year><volume>21</volume><fpage>494</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1038/sj.eye.6702240</pub-id><pub-id pub-id-type="pmid">16518370</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastiaens</surname><given-names>L</given-names></name><name><surname>Galus</surname><given-names>J</given-names></name></person-group><article-title>Comparison of the adult ADHD self report scale screener for DSM-IV and DSM-5 in a dually diagnosed correctional population</article-title><source>Psychiatr Q</source><year>2018</year><volume>89</volume><fpage>505</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1007/s11126-017-9553-4</pub-id><pub-id pub-id-type="pmid">29270886</pub-id></element-citation></ref></ref-list></back></article>